文献速递消化系统肿瘤

肝切除联合mFOLFOX6对比单纯肝切除治疗结直肠癌肝转移的随机II/III期长期随访结果

Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603.
PubMed 文献 · J Clin Oncol · 2026-01-21

JCOG0603研究比较肝切除术后辅助mFOLFOX6与单纯肝切除治疗可切除结直肠癌肝转移,长期随访显示辅助化疗未改善总生存(HR 1.07),但无病生存有改善(HR 0.72),提示辅助mFOLFOX6可能延迟复发但不提高长期生存。

要点

  • 辅助mFOLFOX6未改善可切除CRLM患者长期OS(HR 1.07)。
  • 辅助mFOLFOX6改善DFS(5年DFS 49.7% vs 40.5%,HR 0.72)。
  • 辅助化疗组1例可能死于方案治疗相关毒性。

核心结论

  • 在可切除的结直肠癌肝转移患者中,肝切除术后辅助mFOLFOX6与单纯肝切除相比,长期总生存无差异。
  • 辅助mFOLFOX6可能延迟复发,但未改善长期生存。

研究设计与样本

  • 随机II/III期试验,纳入结直肠腺癌且肝转移数目不限的患者,随机分配至辅助mFOLFOX6组或单纯肝切除组。
  • 主要终点为无病生存(DFS),总生存(OS)为次要终点。

主要发现

  • 中位随访7.7年(针对无病存活患者),辅助化疗组死亡54例(35.8%),单纯肝切除组死亡51例(34.2%),HR 1.07(95% CI 0.73至1.57)。
  • 5年OS辅助化疗组73.4%(95% CI 65.5至79.7),单纯肝切除组80.1%(95% CI 72.6至85.7);7年OS分别为69.4%(95% CI 61.2至76.2)和72.4%(95% CI 64.2至79.1)。
  • 5年DFS辅助化疗组49.7%(95% CI 41.5至57.3),单纯肝切除组40.5%(95% CI 32.5至48.3),HR 0.72(95% CI 0.54至0.97)。
  • 辅助化疗组1例可能死于方案治疗相关毒性,单纯肝切除组1例死于方案后治疗并发症。

临床怎么用

  • 对于可切除的结直肠癌肝转移,肝切除术后辅助mFOLFOX6虽可改善DFS,但未转化为OS获益,临床决策需权衡辅助化疗的毒性风险与复发延迟的潜在获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

JCOG0603 demonstrated improved disease-free survival (DFS) with adjuvant mFOLFOX6 after hepatectomy compared with hepatectomy alone in colorectal liver-only metastasis (CRLM), but the overall survival (OS) data were immature. Here, we report OS after long-term follow-up. Eligible patients with colorectal adenocarcinoma and an unlimited number of liver metastases were randomized to adjuvant mFOLFOX6 or hepatectomy alone. DFS was the primary endpoint, and OS was a secondary endpoint. Between March 2007 and January 2019, 151 and 149 patients were randomized to adjuvant chemotherapy and hepatectomy alone, respectively. At a median follow-up of 7.7 years for disease-free surviving patients, 54 (35.8%) and 51 (34.2%) patients had died in the respective arms, (hazard ratio [HR], 1.07 [95% CI, 0.73 to 1.57]). Five-year OS was 73.4% (95% CI, 65.5 to 79.7) and 80.1% (95% CI, 72.6 to 85.7) and 7-year OS was 69.4% (95% CI, 61.2 to 76.2) and 72.4% (95% CI, 64.2 to 79.1), respectively. One patient in the adjuvant chemotherapy arm possibly died of protocol treatment-related toxicity, and one in the hepatectomy-alone arm died of post-protocol treatment complications. Five-year DFS was respectively 49.7% (95% CI, 41.5 to 57.3) and 40.5% (95% CI, 32.5 to 48.3) in the adjuvant chemotherapy and hepatectomy-alone arms (HR, 0.72 [95% CI, 0.54 to 0.97]). Long-term OS did not differ with adjuvant mFOLFOX6 compared with hepatectomy alone in resectable CRLM. Adjuvant mFOLFOX6 may delay recurrence but did not improve long-term survival.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kanemitsu Y, Shimizu Y, Mizusawa J, et al. Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603. J Clin Oncol. 2026. PMID: 41564372. doi:10.1200/JCO-25-01231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。